Protara Therapeutics (NASDAQ:TARA - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Protara Therapeutics to post earnings of ($0.47) per share for the quarter.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.09. On average, analysts expect Protara Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Protara Therapeutics Stock Performance
Protara Therapeutics stock traded down $0.12 on Tuesday, reaching $3.40. The company's stock had a trading volume of 638,149 shares, compared to its average volume of 781,967. The company has a market cap of $125.01 million, a price-to-earnings ratio of -1.21 and a beta of 1.60. The business's fifty day moving average price is $4.02 and its 200 day moving average price is $4.02. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48.
Wall Street Analyst Weigh In
A number of equities analysts have commented on TARA shares. Lifesci Capital started coverage on Protara Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Protara Therapeutics in a research report on Friday, March 14th. They set an "overweight" rating for the company. Scotiabank assumed coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Monday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Protara Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $20.40.
View Our Latest Report on Protara Therapeutics
Insider Activity at Protara Therapeutics
In related news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the sale, the insider now owns 98,861 shares in the company, valued at approximately $447,840.33. This represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 12.50% of the stock is currently owned by corporate insiders.
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
See Also
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
